Factors associated with discontinuation of pulmonary vasodilator therapy in children with bronchopulmonary dysplasia-associated pulmonary hypertension

Catherine M. Avitabile, Xuemei Zhang, Steve B. Ampah, Yan Wang, Devon Ash, Kathleen Nilan, Laura Mercer-Rosa, Julie L. Fierro, David B. Frank, Kathleen A. Gibbs

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To evaluate factors associated with discontinuation of pulmonary vasodilator therapy in bronchopulmonary dysplasia-related pulmonary hypertension (BPD-PH). Study design: Retrospective study of neonatal, echocardiographic, and cardiac catheterization data in 121 infants with BPD-PH discharged on pulmonary vasodilator therapy from 2009–2020 and followed into childhood. Result: After median 4.4 years, medications were discontinued in 58%. Those in whom medications were discontinued had fewer days of invasive support, less severe BPD, lower incidence of PDA closure or cardiac catheterization, and higher incidence of fundoplication or tracheostomy decannulation (p < 0.05). On multivariable analysis, likelihood of medication discontinuation was lower with longer period of invasive respiratory support [HR 0.95 (CI:0.91–0.99), p = 0.01] and worse RV dilation on pre-discharge echocardiogram [HR 0.13 (CI:0.03–0.70), p = 0.017]. In those with tracheostomy, likelihood of medication discontinuation was higher with decannulation [HR 10.78 (CI:1.98–58.59), p < 0.001]. Conclusion: In BPD-PH, childhood discontinuation of pulmonary vasodilator therapy is associated with markers of disease severity.

Original languageEnglish
Pages (from-to)1246-1254
Number of pages9
JournalJournal of Perinatology
Volume42
Issue number9
DOIs
StatePublished - Sep 2022
Externally publishedYes

Fingerprint

Dive into the research topics of 'Factors associated with discontinuation of pulmonary vasodilator therapy in children with bronchopulmonary dysplasia-associated pulmonary hypertension'. Together they form a unique fingerprint.

Cite this